. Author manuscript; available in PMC: 2021 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2020 Apr 20;26(8):1414–1424. doi: 10.1016/j.bbmt.2020.03.028

Table 5.

Summary of prospective upfront tandem ASCT/alloSCT studies

Study	n	Induction	AlloSCT	OS	TRM	Other
IFM99-03^{7, 9}	65 (46 completed)	VAD	Bu/Flu/AT G	Median: 35 mos	10.9%	Del(13q) (FISH) and β2MG >3
PETHEMA/GEM −2000¹⁰	25	VBMCP/VBAD	FluMel	5 yrs: 62%	16%	Not in nCR/CR post-ASCT
DSMM V⁴⁶	126	Anthracycline/dex-based followed by one cycle of ifosfamide/epirubi cin/etoposide	FluMel	Median: 70.2 mos	12.7% at 2 yrs	Del(13q) (FISH)
BMT-CTN 0102¹²	226 (185 completed)	Not specified	TBI 200 cGy	3 yrs: 77%	11% at 3 yrs
HOVON-50/54¹⁵	122	VAD or TAD	TBI 2 Gy	6 yrs: 55%	16% at 6 yrs (NRM)
Bruno et al.^{8, 13}	80 (58 completed)	VAD	TBI 200 cGy	Median NR after median f/u of 7 years	10%
EBMT-NMAM2000^{14, 16}	108	Not specified	TBI 2 Gy + Flu	5 yrs: 65% 8 yrs: 49%	12% at 3 yrs (NRM)
Kroger et al.⁴⁸	73	Ida/Dex, VAD, or BD	Flu/Mel/AT G	5 yrs: 54%	23% at 1 yr
CALGB 100001	57 (49 completed)	Not specified	Flu/Cy	Median: 6.6 yrs	2% at 6 month s

Abbreviations: β2MG, β2-microglobulin; BD, bortezomib/dexamethasone; Bu, busulfan; CR, complete response; Cy, cyclophosphamide; Dex, dexamethasone; Flu, fludarabine; Ida, idarubicin; nCR, near complete response; NRM, non-relapse mortality; TAD, thalidomide/doxorubicin/dexamethasone; TBI, total body irradiation; VAD, vincristine/doxorubicin/dexamethasone; VBAD, vincristine/carmustine/doxorubicin/dexamethasone; VBMCP, vincristine/carmustine/melphalan/cyclophosphamide/prednisone.